Patent ID: 8338480

Claim:
A method of treating a mammalian subject having a condition selected from the group consisting of insulin resistance syndrome and Type II Diabetes, comprising administering to the subject a Compound of Formula I or a pharmaceutically acceptable salt thereof wherein: m is 0, 2 or 4; and X is —OR 7 , wherein R 7 is hydrogen or alkyl having from 1 to 3 carbon atoms; R 6 is hydrogen, O or hydroxy; and three of R 1 , R 2 , R 3 , R 4 and R 5 are hydrogen and the remainder are independently selected from the group consisting of hydrogen, halo, hydroxy, methyl, ethyl, perfluoromethyl, methoxy, ethoxy, and perfluoromethoxy; or X is —NR 8 R 9 , wherein R 8 is hydrogen or hydroxy and R 9 is hydrogen, methyl or ethyl; R 6 is hydrogen; and three of R 1 , R 2 , R 3 , R 4 and R 5 are hydrogen and the remainder are independently selected from the group consisting of hydrogen, halo, methyl, ethyl, perfluoromethyl, methoxy, ethoxy, and perfluoromethoxy; and a direct PPAR-gamma agonist in a combined amount effective to treat the metabolic condition wherein the Compound of Formula I or salt thereof is administered in an amount that is less than the usual therapeutic dose when administered alone.